Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

Phase 0 lead-in trial of Pitavastatin in primary and recurrent Glioblastoma patients Ended

2023-505743-38-00 Glioblastoma Multiforme 3 2024-01-18
Phase 1b safety study of xevinapant, weekly cisplatin, and radiotherapy in participants with unresected LA SCCHN Ended

2023-505796-76-00 Locally Advanced Squamous Cell Carcinoma of the Head an 3 2024-01-18
(VELA) Study of BLU-222 in Advanced Solid Tumors Ended

2022-502528-29-00 HR+ Breast Cancer CCNE1 Amplification HER2-negative Bre 7 2024-01-09
Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment Ended

2023-503919-15-00 Prostatic Neoplasms 3 2024-01-09
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3… Ended

2023-505322-34-00 Advanced or metastatic solid tumors 1 2024-01-08
A study to evaluate the safety, tolerability and distribution of TB0010 in head and neck squamous cell carcinoma Ended

2024-517779-19-00 EGFR-Positive Head and Neck Squamous Cell Carcinoma 1 2024-01-05
A Phase 1/2a, First in Human, Open-Label, Multicenter, Dose Escalation Study with Expansion Cohorts to Evaluate the Safety, Tolerability, an… Ended

2023-505576-29-00 Advanced solid tumors 7 2024-01-03
Randomized Phase 2 Study of DKN-01 Plus FOLFIRI/FOLFOX and Bevacizumab Versus FOLFIRI/FOLFOX and Bevacizumab as Second-line Treatment of Adv… Ended

2022-501465-40-00 Colorectal Cancer 4 2023-12-22
A clinical trial to learn how an investigational drug (vimseltinib) is absorbed, distributed, broken down, and removed from the body when gi… Ended

2023-503415-15-00 Tenosynovial Giant Cell Tumor (TGCT) 3 2023-12-21
RVU 120 (SEL120) to be tested in for treatment patients with solid tumors who have failed previous available standard therapy Ended

2024-515131-30-00 Relapsed / Refractory Metastatic or Advanced Solid Tumo 4 2023-12-18
A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors Ended

2022-502348-11-00 Pancreatic Neoplasms 1 2023-12-15
First Clinical Trial with activated regulatory T-cells in patients early after haematopoietic stem cell transplantation (HSCT) Ended

2024-516599-14-00 Leukaemia 7 2023-12-13
Focus Green: Fluorescence-guided resection Of Colorectal liver metastases Using SGM-101 and Indocyanine GREEN Ended

2023-504615-33-00 colorectal livermetastases 4 2023-12-12
Study comparing radiotherapy combined with cetuximab + Xevinapant (study drug) with radiotherapy combined with cetuximab + placebo in patien… Ended

2022-502584-38-00 Locally advanced squamous cell carcinoma of the head an 5 2023-12-12
FLUOPANC II: A performance study of SGM-101, a fluorochrome-labeled anti-carcinoembryonic antigen monoclonal antibody for fluorescence-guide… Ended

2023-510481-27-00 Pancreatic tumor 4 2023-12-11
Study of ART0380 in Advanced/Metastatic Solid Tumors Patients (ARTIST) Ended

2023-504153-12-00 Advanced or Metastatic Solid Tumors 4 2023-12-07
First-in-human interleukin-15-transpresenting Wilms’ tumor protein 1-targeting autologous dendritic cell vaccination in cancer patients Ended

2024-515296-35-00 Histologically or cytologically confirmed solid tumor o 7 2023-12-06
A Study to Evaluate Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants with Relapsed or … Ended

2023-503689-21-00 Multiple myeloma (MM) 9 2023-12-05
Phase 1/2a Open-Label, Dose-Escalation, Multicenter, First in-Human, Consecutive-Cohort, Clinical Trial of BI 1910, a Monoclonal Antibody to… Ended

2022-503066-74-00 Advanced solid tumors 7 2023-12-04
Phase 1/2 Study of BDC-1001 as a Single Agent and in Combination with Nivolumab in Patients with Advanced HER2-Expressing Solid Tumors Ended

2024-518411-19-00 Advanced HER2-Expressing Solid Tumors. 9 2023-12-04
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination with a Checkpoint Inhibitor with or without Stand… Ended

2022-502615-11-00 Locally Advanced or Metastatic Solid Tumors 1 2023-11-29
Randomized, non-comparative, open-label early phase Ib study with OBT076 or OBT076 followed by Balstilimab in patients with Adenoid Cystic C… Ended

2023-503270-20-00 recurrent or metastatic Adenoid Cystic Carcinoma of the 3 2023-11-29
A Study Evaluating the Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients with Surgically Resectable Hepatocellular C… Ended

2022-502840-11-00 Hepatocellular Carcinoma (Morpheus-Neo HCC) 9 2023-11-28
A PHASE 2 STUDY EVALUATING INCB099280 IN PARTICIPANTS WITH SELECT SOLID TUMORS WHO ARE IMMUNE CHECKPOINT INHIBITOR–NAÏVE Ended

2022-502716-37-00 Recurrent or advanced/metastatic solid tumors who are i 4 2023-11-27